Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-08 8:18 pm Purchase | 2024-03-28 | 13G | iBio, Inc. IBIO | Opaleye Management Inc. | 650,000 7.630% | 650,000 (New Position) | Filing History |
| 2024-02-14 7:48 pm Sale | 2023-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 6,070,000 5.510% | -5,000 (-0.08%) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 307,983 9.090% | 224,173 (+267.48%) | Filing History |
| 2024-02-09 4:05 pm Sale | 2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 0 0.000% | -2,810,000 (Position Closed) | Filing History |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,820,000 10.880% | 45,000 (+1.19%) | Filing History |
| 2024-02-09 4:05 pm Sale | 2023-12-31 | 13D | TRACON Pharmaceuticals, Inc. TCON | Opaleye Management Inc. | 0 0.000% | -125,919 (Position Closed) | Filing History |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,524,887 9.840% | 354,887 (+16.35%) | Filing History |
| 2024-01-05 4:05 pm Purchase | 2023-12-27 | 13G | Context Therapeutics Inc. CNTX | Opaleye Management Inc. | 820,000 5.140% | 820,000 (New Position) | Filing History |
| 2023-04-12 4:15 pm Purchase | 2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 2,810,000 5.390% | 2,810,000 (New Position) | Filing History |
| 2023-02-13 4:05 pm Sale | 2022-12-30 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 0 0.000% | -5,580,000 (Position Closed) | Filing History |
| 2023-02-13 4:05 pm Unchanged | 2022-12-30 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 83,810 5.690% | 0 (Unchanged) | Filing History |
| 2023-02-13 06:11 am Purchase | 2022-12-30 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 6,075,000 7.890% | 100,200 (+1.68%) | Filing History |
| 2023-01-20 7:09 pm Purchase | 2022-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 1,560,000 3.610% | 616,298 (+65.31%) | Filing History |
| 2023-01-20 4:59 pm Purchase | 2022-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,775,000 12.820% | 490,000 (+14.92%) | Filing History |
| 2023-01-20 4:53 pm Sale | 2022-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,170,000 8.580% | -215,000 (-9.01%) | Filing History |
| 2022-06-10 4:05 pm Purchase | 2022-06-07 | 13D | TELA Bio, Inc. TELA | Opaleye Management Inc. | 1,557,500 10.690% | 806,332 (+107.34%) | Filing History |
| 2022-06-03 4:05 pm Purchase | 2022-06-01 | 13G | TELA Bio, Inc. TELA | Opaleye Management Inc. | 751,168 5.160% | 751,168 (New Position) | Filing History |
| 2022-02-18 4:32 pm Purchase | 2022-02-15 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 943,702 5.320% | 943,702 (New Position) | Filing History |
| 2022-01-31 9:02 pm Unchanged | 2021-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-01-31 8:41 pm Purchase | 2021-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 5,580,000 6.400% | 1,623,500 (+41.03%) | Filing History |